Clinical Stage II Cutaneous Melanoma AJCC v8
specificStage III includes: Any T, Tis, N1 or More, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N1: One tumor-involved node or in-transit, satellite, and/or microsatellite metastases with no tumor-involved nodes. N2: Two or three tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with one tumor-involved node. N3: Four or more tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with two or more tumor-inv
7
Centers
2
Active Trials
—
Cancer Funding
Top Centers for Clinical Stage II Cutaneous Melanoma AJCC v8(7)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive High-Volume Research Center | 73.2 |
| 2 | USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive High-Volume Research Center | 73.2 |
| 3 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive | 50.7 |
| 4 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive | 50.7 |
| 5 | Fred Hutch Cancer CenterSeattle, WA NCI Comprehensive | 50.7 |
| 6 | UCLA Jonsson Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive | 50.7 |
| 7 | Boston University Cancer CenterBoston, MA | 50.7 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →